
Turning Scientific Insight into Therapeutic Impact
After antibiotics, antivirals, and targeted cancer therapies, we are entering a new era in medicine by targeting and depleting misfolded proteins that drive chronic protein aggregation diseases.
Roger M. Nitsch, CEO